GOYAL ARJUN 4
4 · Centessa Pharmaceuticals plc · Filed Jun 4, 2021
Insider Transaction Report
Form 4
GOYAL ARJUN
Director
Transactions
- Conversion
Ordinary Shares
2021-06-02+3,095,909→ 3,095,909 total(indirect: See footnote) - Conversion
Ordinary Shares
2021-06-02+85,909→ 85,909 total(indirect: See footnote) - Conversion
Series A Preferred Shares
2021-06-02−85,909→ 0 total(indirect: See footnote)→ Ordinary Shares (85,909 underlying) - Purchase
Ordinary Shares
2021-06-02$20.00/sh+729,750$14,595,000→ 3,825,659 total(indirect: See footnote) - Purchase
Ordinary Shares
2021-06-02$20.00/sh+20,250$405,000→ 106,159 total(indirect: See footnote) - Award
Series A Preferred Shares
2021-01-29$11.00/sh+3,095,909$34,054,999→ 3,095,909 total(indirect: See footnote)→ Ordinary Shares (3,095,909 underlying) - Award
Series A Preferred Shares
2021-01-29$11.00/sh+85,909$944,999→ 85,909 total(indirect: See footnote)→ Ordinary Shares (85,909 underlying) - Conversion
Series A Preferred Shares
2021-06-02−3,095,909→ 0 total(indirect: See footnote)→ Ordinary Shares (3,095,909 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.
- [F3]Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F4]Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- [F5]This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
- [F6]On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.